Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of miRNA (micro-ribonucleic acid) composition to preparing non-small cell lung cancer resisting medicines

A composition and anti-tumor drug technology, applied in the field of genetic engineering, can solve problems such as low survival rate, easy drug resistance of patients, loss of surgery opportunities, etc., and achieve the effect of promoting normalization

Inactive Publication Date: 2016-05-11
JIANGSU PROVINCE HOSPITAL
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Non-small cell lung cancer accounts for 80% of all lung cancers, and more than two-thirds of lung cancer patients have metastasized at the time of diagnosis, often losing the opportunity for surgery, and the chemotherapy drugs for lung cancer are not effective, and patients are prone to drug resistance. The survival rate is less than 5%, and there is an urgent need to find new and effective treatments for lung cancer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of miRNA (micro-ribonucleic acid) composition to preparing non-small cell lung cancer resisting medicines
  • Application of miRNA (micro-ribonucleic acid) composition to preparing non-small cell lung cancer resisting medicines
  • Application of miRNA (micro-ribonucleic acid) composition to preparing non-small cell lung cancer resisting medicines

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0033] The preparation method of pre-miR-1: 1. The pre-miR-1 sequence (pUC57-Simple-pre-miR-1) was synthesized by Nanjing Kaiji Biotechnology Development Co., Ltd. The target vector pYr-mir30-shRNA-2 was purchased from Changsha Yingrun Biotechnology Co., Ltd.; 2. The pre-miR-1 fragment was cloned into the pYr-mir30-shRNA-2 vector; 3. The clone was confirmed by sequencing; 4. Plasmid extraction.

[0034] The preparation method of pre-miR-206 is the same as that of pre-miR-1.

[0035] anti-miR-31 is an artificially synthesized miR-31 repressor that inhibits the expression of endogenous mature miR-31), and pre-miR-1, pre- The co-transfection of miR-206 and anti-miR-31 into A549 and H460 cells simultaneously up-regulated the expression of miR-1, miR-206 and down-regulated the expression of miR31.

Embodiment 1

[0037] 1. Differential expression of miRNAs in non-small cell lung cancer tumor-associated fibroblasts and normal fibroblasts

[0038] (1): Gene chip detection of miRNA expression levels in tumor-associated fibroblasts (CAF) and paired normal fibroblasts (NF) of 3 patients with non-small cell lung cancer;

[0039] 1. Chip preparation and analysis: According to the requirements of LC Sciences in the United States, lung cancer cell samples were prepared, and the chip was prepared by LC Sciences, and SangermiRBaseV10.0 version completed the chip analysis.

[0040] 2. Chip results: the experimental data comes from LCSciences, and the results are as follows: figure 1 shown.

[0041] 3. Analysis of the results: Compared with NF, the down-regulation of miR-1 / miR-206 was the most obvious in CAF; the up-regulation of miR-31 was the most obvious.

[0042] (2) qRT-PCR analysis of the expression levels of miR-1, miR-206 and miR-31 in tumor-associated fibroblasts (CAF) and paired normal ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of genetic engineering, and particularly relates to application of a novel miRNA (micro-ribonucleic acid) composition to preparing non-small cell lung cancer resisting medicines. Transformation of lung tumor-associated fibroblasts of non-small cell lung cancer to normal fibroblasts can be promoted by means of changing expression level of the miRNA composition; the novel miRNA composition includes miR-1, miR-206 and miR-31. The application has the advantages that the miR-1 / miR-206 are simultaneously over expressed in the lung tumor-associated fibroblasts of the non-small cell lung cancer, the miR-31 is expressed at low level in the lung tumor-associated fibroblasts of the non-small cell lung cancer, accordingly, transformation of the lung tumor-associated fibroblasts to the normal fibroblasts can be promoted, anti-tumor effects can be realized at cell and animal level, and the miRNA composition has potential anti-tumor application value.

Description

technical field [0001] The invention belongs to the field of genetic engineering, in particular to the construction of a method for transforming non-small cell lung cancer tumor-associated fibroblasts into normal fibroblasts and its application in anti-tumor therapy Background technique [0002] Fibroblasts are key cellular components of human tissues and tumors and can be divided into resting and activated fibroblasts. For example, the fibroblasts are highly activated at wound healing sites. Activated fibroblasts invade the lesion and produce extracellular matrix (Extracellular matrix, ECM), which acts as a scaffold for other cells. Once the wound is repaired, the activated fibroblasts return to a resting phenotype, which is called normal fibroblasts (Normal Fibroblasts, NFs). At present, it is believed that the development of tumor is not only determined by malignant cancer cells, but also requires the participation of activated tumor fibroblasts or tumor-associated fibr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K48/00A61K31/7088A61P35/00
CPCA61K31/7088A61K2300/00
Inventor 沈华束永前刘连科
Owner JIANGSU PROVINCE HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com